Jefferies analyst Kaumil Gajrawala initiated coverage of PetIQ with a Buy rating and $22 price target. The pet health and wellness company is benefiting from pet owners increasingly adopting a preventative medication and the uptake of third-party pet meds and a gradual shift to value-priced in-house alternatives “underpin reasonable growth & margin expectations,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PETQ:
